Global Orthopedic Biomaterial Market Forecast till 2027

$4450$6250

The global orthopedic biomaterials market is estimated to record the highest CAGR of 10. 5% during the review period, to surpass USD 40,519.52 million by 2027.

Description

Global Orthopedic Biomaterial Market—Forecast till 2027

Information by

  • Product (Reconstructive Joint Replacement, SpinalImplants, Dental Implants,Trauma, Orthobiologics),
  • Material Class (Metal andNon-Metal),
  • Application (Joint Replacement, Fracture Fixation, Tissue Fixation, Implant Surgery,Visco Supplementation),
  • End User (Hospitals & Clinics, Ambulatory Surgical Centers), and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa)

 

Market Overview
The global orthopedic biomaterials market size is estimated to record the highest CAGR of 10. 5% during the review period, to surpass USD 40,519.52 million by 2027.

Orthopedic biomaterials are embedded in the human body as constituents. These gadgets are intended to play out certain organic capacities by subbing or fixing various tissues like bone, ligament, or tendons and ligaments and surprisingly directing bone fix when important.
The development of the orthopedic biomaterials market is driven by variables, for example, the developing interest in cutting-edge orthopedic biomaterials and the expanding pervasiveness of orthopedic sicknesses.

Moreover, the expanding commonness of constant sicknesses sets out rewarding freedom for the market. Notwithstanding, the absence of repayment and a questionable administrative structure are probably going to limit the market development. Additionally, the global market is propelled by the increasing older population leading to an increase in the patient population and growing demand for next-generation orthopedic biomaterials

Market Segmentation
The global orthopedic biomaterials market is classified in terms of product, material class, application, and end-user.
By Product type, the global market has been segmented into Reconstructive Joint Replacements, Spinal Implants, Dental Implants, Trauma, Orthobiologics, and others.
Based on Material Class the market is subdivided into Metal and Non-Metal.
By Application, the market is further classified into Joint Replacement, Fracture Fixation, Tissue Fixation, Tissue Fixation, Implant Surgery, and Viscosupplementation.
By End User segment the market is segregated into Hospitals & Clinics, Ambulatory Surgical Centers, and Others.

Regional Analysis

Americas:
The Americas ruled the orthopedic biomaterials market in 2019 and is probably going to keep during the appraisal time frame too. This can be credited to the high commonness of orthopedic illnesses, item dispatches, and innovative progression around here. The appeal for orthopedic biomaterials and the satisfactory accessibility of talented experts in the locale are relied upon to fuel the local market development. The developing older populace is additionally bringing about the development of the orthopedic biomaterials market in the Americas. According to the Administration for Community Living, in the Americas, throughout the most recent ten years, the populace matured 65 and overdeveloped from 37.2 million out of 2006 to 49.2 million out of 2016.

Europe stood firm on the second-biggest footing in the orthopedic biomaterials market in 2019 and is expected to observe critical development over the gauge time frame because of a bigger number of patients and the accessibility of items in the area.

The Asia-Pacific is expected to record the most elevated development rate during the conjecture period.

The orthopedic biomaterials market in the Middle East and Africa has been filling consistently as of late. The key variables pushing the development of the orthopedic market are expanding the pervasiveness of orthopedics issues and subsidizing by private players and government bodies.

Major Players
The Key Companies Covered in the global orthopedic biomaterials Report are Stryker (US), CoorsTek Inc. (US), Zimmer Biomet Holdings Inc. (US), Institut Straumann AG (Switzerland), Kyocera Corporation (Japan), Smith & Nephew plc (UK), 3M (US), Nobel Biocare Services AG(Switzerland), Medtronicplc (Ireland), and DePuy Synthes (US).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 22 1.1 OVERVIEW 22 1.1.1 MARKET SYNOPSIS 22 2 MARKET INTRODUCTION 23 2.1 SCOPE OF THE STUDY 23 2.2 RESEARCH OBJECTIVE 23 2.3 LIST OF ASSUMPTIONS & LIMITATIONS 23 3 RESEARCH METHODOLOGY 25 3.1 OVERVIEW 25 3.2 DATA MINING 25 3.3 SECONDARY RESEARCH 26 3.4 PRIMARY RESEARCH 27 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 27 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 28 3.5 FORECASTING TECHNIQUES 29 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30 3.6.1 BOTTOM-UP APPROACH 31 3.6.2 TOP-DOWN APPROACH 31 3.7 DATA TRIANGULATION 32 3.8 VALIDATION 32 4 MARKET DYNAMICS 33 4.1 OVERVIEW 33 4.2 DRIVERS 34 4.2.1 GROWING DEMAND FOR NEXT-GENERATION ORTHOPEDIC BIOMATERIALS 34 4.2.2 INCREASING OLDER POPULATION LEADING TO INCREASE IN THE PATIENT POPULATION 34 4.2.3 RISING PREVALENCE OF ORTHOPEDIC DISEASES 34 4.3 RESTRAINT 35 4.3.1 LACK OF REIMBURSEMENTS 35 4.3.2 AMBIGUOUS REGULATORY FRAMEWORK 35 4.4 OPPORTUNITY 36 4.4.1 TECHNOLOGICAL ADVANCEMENTS IN THE MEDICAL IMPLANTS MARKET 36 4.4.2 ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS 36 5 MARKET FACTOR ANALYSIS 37 5.1 VALUE CHAIN ANALYSIS 37 5.1.1 R&D AND DESIGNING 38 5.1.2 MANUFACTURING 38 5.1.3 DISTRIBUTION 38 5.1.4 MARKETING AND SALES 38 5.2 PORTER’S FIVE FORCES MODEL 39 5.2.1 THREAT OF NEW ENTRANTS 40 5.2.2 BARGAINING POWER OF SUPPLIERS 40 5.2.3 THREAT OF SUBSTITUTES 40 5.2.4 BARGAINING POWER OF BUYERS 40 5.2.5 INTENSITY OFRIVALRY 40 5.3 COVID-19 IMPACT ANALYSIS 41 5.3.1 IMPACT ON R&D 41 5.3.2 IMPACT ON SUPPLY CHAIN 41 5.3.3 IMPACT ON MANUFACTURERS 41 6 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY PRODUCT 42 6.1 OVERVIEW 42 6.2 RECONSTRUCTIVE JOINT REPLACEMENTS 44 6.2.1 KNEE REPLACEMENT IMPLANTS 45 6.2.2 HIP REPLACEMENT IMPLANTS 46 6.2.3 EXTREMITIES 46 6.3 SPINAL IMPLANTS 47 6.3.1 SPINAL FUSION IMPLANTS 48 6.3.2 VERTEBRAL COMPRESSION FRACTURE (VCF) DEVICES 49 6.3.3 MOTION PRESERVATION DEVICES/NON-FUSION DEVICES 49 6.4 DENTAL IMPLANTS 50 6.4.1 ROOT FORM DENTAL IMPLANTS 51 6.4.2 PLATE FORM DENTAL IMPLANTS 51 6.5 TRAUMA 52 6.6 ORTHOBIOLOGICS 52 6.6.1 VISCOSUPPLEMENTATION 54 6.6.2 DEMINERALIZED BONE MATRIX (DBM) 54 6.6.3 SYNTHETIC BONE SUBSTITUTES 55 6.6.4 BONE MORPHOGENETIC PROTEIN (BMP) 55 6.6.5 ALLOGRAFT 56 7 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY MATERIAL CLASS 57 7.1 OVERVIEW 57 7.2 METAL 58 7.2.1 STAINLESS STEEL 59 7.2.2 TITANIUM ALLOY 59 7.2.3 COBALT ALLOY 60 7.3 NON-METAL 60 7.3.1 CERAMIC 61 7.3.1.1 ALUMINA 62 7.3.1.2 CALCIUM PHOSPHATE 62 7.3.1.3 ZIRCONIUM DIOXIDE 63 7.3.1.4 CARBON 63 7.3.2 POLYMERIC 63 7.3.2.1 POLYMETHYLMETHACRYLATE (PMMA) 64 7.3.2.2 POLYETHYLENE 65 7.3.2.3 SILICONE 65 7.3.2.4 POLYESTER 65 8 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY APPLICATION 66 8.1 OVERVIEW 66 8.2 JOINT REPLACEMENT 67 8.2.1 HIP REPLACEMENT 68 8.2.2 KNEE REPLACEMENT 68 8.2.3 SHOULDER AND ELBOW REPLACEMENT 69 8.3 FRACTURE FIXATION 69 8.4 TISSUE FIXATION 70 8.5 IMPLANT SURGERY 70 8.6 VISCOSUPPLEMENTATION 71 8.7 OTHERS 71 9 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY END USER 72 9.1 OVERVIEW 72 9.2 HOSPITALS & CLINICS 73 9.3 AMBULATORY SURGICAL CENTERS 73 10 GLOBAL ORTHOPEDIC BIOMATERIALS MARKET, BY REGION 74 10.1 OVERVIEW 74 10.2 AMERICAS 76 10.2.1 NORTH AMERICA 81 10.2.1.1 US 87 10.2.1.2 CANADA 91 10.2.2 LATIN AMERICA 96 10.3 EUROPE 101 10.3.1 WESTERN EUROPE 106 10.3.1.1 GERMANY 112 10.3.1.2 FRANCE 117 10.3.1.3 UK 122 10.3.1.4 ITALY 126 10.3.1.5 SPAIN 131 10.3.1.6 REST OF WESTERN EUROPE 136 10.3.2 EASTERN EUROPE 141 10.4 ASIA-PACIFIC 146 10.4.1 CHINA 152 10.4.2 JAPAN 157 10.4.3 INDIA 162 10.4.4 AUSTRALIA 167 10.4.5 SOUTH KOREA 172 10.4.6 REST OF ASIA-PACIFIC 177 10.5 MIDDLE EAST & AFRICA 182 10.5.1 MIDDLE EAST 187 10.5.2 AFRICA 192 11 COMPETITIVE LANDSCAPE 197 11.1 OVERVIEW 197 11.2 COMPETITIVE BENCHMARKING 198 11.3 COMPETITOR DASHBOARD 199 11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL ORTHOPEDIC BIOMATERIALS MARKET 199 11.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ORTHOPEDIC BIOMATERIALS MARKET 200 11.6 KEY DEVELOPMENT ANALYSIS 200 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 201 11.7.1 PRODUCT LAUNCHES/PRODUCT APPROVALS 201 11.7.2 ACQUISITIONS 202 11.7.3 COLLABORATIONS/JOINT VENTURES 203 11.7.4 EXPANSIONS 203 12 COMPANY PROFILES 204 12.1 STRYKER 204 12.1.1 COMPANY OVERVIEW 204 12.1.2 FINANCIAL OVERVIEW 205 12.1.3 PRODUCTS/SERVICES OFFERED 205 12.1.4 KEY DEVELOPMENTS 206 12.1.5 SWOT ANALYSIS 207 12.1.6 KEY STRATEGIES 207 12.2 COORSTEK INC. 208 12.2.1 COMPANY OVERVIEW 208 12.2.2 FINANCIAL OVERVIEW 208 12.2.3 PRODUCTS/SERVICES OFFERED 208 12.2.4 KEY DEVELOPMENTS 209 12.2.5 SWOT ANALYSIS 209 12.2.6 KEY STRATEGIES 209 12.3 ZIMMER BIOMET HOLDINGS INC. 210 12.3.1 COMPANY OVERVIEWS 210 12.3.2 FINANCIAL OVERVIEW 210 12.3.3 PRODUCTS/SERVICES OFFERED 211 12.3.4 KEY DEVELOPMENTS 212 12.3.5 SWOT ANALYSIS 213 12.3.6 KEY STRATEGIES 213 12.4 INSTITUT STRAUMANN AG 214 12.4.1 COMPANY OVERVIEW 214 12.4.2 FINANCIAL OVERVIEW 214 12.4.3 PRODUCTS/SERVICES OFFERED 215 12.4.4 KEY DEVELOPMENTS 215 12.4.5 SWOT ANALYSIS 216 12.4.6 KEY STRATEGIES 216 12.5 KYOCERA CORPORATION 217 12.5.1 COMPANY OVERVIEWS 217 12.5.2 FINANCIAL OVERVIEW 217 12.5.3 PRODUCTS/SERVICES OFFERED 218 12.5.4 KEY DEVELOPMENTS 218 12.5.5 SWOT ANALYSIS 218 12.5.6 KEY STRATEGIES 219 12.6 SMITH& NEPHEW 220 12.6.1 COMPANY OVERVIEW 220 12.6.2 FINANCIAL OVERVIEW 220 12.6.3 PRODUCTS/SERVICES OFFERED 221 12.6.4 KEY DEVELOPMENTS 221 12.6.5 SWOT ANALYSIS 222 12.6.6 KEY STRATEGIES 222 12.7 3M 223 12.7.1 COMPANY OVERVIEW 223 12.7.2 FINANCIAL OVERVIEW 224 12.7.3 PRODUCTS/SERVICES OFFERED 225 12.7.4 KEY DEVELOPMENTS 225 12.7.5 SWOT ANALYSIS 226 12.7.6 KEY STRATEGIES 226 12.8 NOBEL BIOCARE HOLDING AG 227 12.8.1 COMPANY OVERVIEW 227 12.8.2 FINANCIAL OVERVIEW 228 12.8.3 PRODUCTS/SERVICES OFFERED 229 12.8.4 KEY DEVELOPMENTS 229 12.8.5 SWOT ANALYSIS 230 12.8.6 KEY STRATEGIES 230 12.9 MEDTRONIC PLC 231 12.9.1 COMPANY OVERVIEW 231 12.9.2 FINANCIAL OVERVIEW 231 12.9.3 PRODUCTS/SERVICES OFFERED 232 12.9.4 KEY DEVELOPMENTS 232 12.9.5 SWOT ANALYSIS 233 12.9.6 KEY STRATEGIES 233 12.10 DEPUY SYNTHES 234 12.10.1 COMPANY OVERVIEW 234 12.10.2 FINANCIAL OVERVIEW 235 12.10.3 PRODUCTS/SERVICES OFFERED 236 12.10.4 KEY DEVELOPMENTS 236 12.10.5 SWOT ANALYSIS 237 12.10.6 KEY STRATEGIES 237 13 APPENDIX 238 13.1 REFERENCES 238 13.2 RELATED REPORTS 238